Search research articles
Contact Us
Filters
Showing results (31-40 of 181) with videos related to
Page
of 19
Sort By:
Hematology/Oncology and Stem Cell Therapy
|
August 24, 2017
Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report
Prajwal Boddu, Ellen Schlette, Beenu Thakral, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 25, 2012
Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine
Elias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi, et al.
Cancer
|
June 12, 2009
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase
Yesid Alvarado, Hagop Kantarjian, Susan O'Brien, et al.
Cancer
|
June 22, 2010
Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome
Amit Lahoti, Hagop Kantarjian, Abdulla K Salahudeen, et al.
Cancer
|
August 30, 2008
Clofarabine combinations as acute myeloid leukemia salvage therapy
Stefan Faderl, Alessandra Ferrajoli, William Wierda, et al.
Cancer
|
October 26, 2007
Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies
Gautam Borthakur, E Lin, Stefan Faderl, et al.
Leukemia & Lymphoma
|
October 30, 2009
p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy
Ellen J Schlette, Joan Admirand, William Wierda, et al.
Haematologica
|
January 25, 2012
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy
Naveen Pemmaraju, Hagop Kantarjian, Jianqin Shan, et al.
Blood
|
October 30, 2010
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
Elias Jabbour, Hagop Kantarjian, Susan O'Brien, et al.
Blood
|
January 10, 2015
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
Preetesh Jain, Michael Keating, William Wierda, et al.
Page
of 19
Search research articles
Search
Showing results (31-40 of 181) with videos related to
Sort By:
Page
of 19
Hematology/Oncology and Stem Cell Therapy
|
August 24, 2017
Acute promyelocytic leukemia in a patient with chronic lymphocytic leukemia-A case report
Prajwal Boddu, Ellen Schlette, Beenu Thakral, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 25, 2012
Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine
Elias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi, et al.
Cancer
|
June 12, 2009
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase
Yesid Alvarado, Hagop Kantarjian, Susan O'Brien, et al.
Cancer
|
June 22, 2010
Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome
Amit Lahoti, Hagop Kantarjian, Abdulla K Salahudeen, et al.
Cancer
|
August 30, 2008
Clofarabine combinations as acute myeloid leukemia salvage therapy
Stefan Faderl, Alessandra Ferrajoli, William Wierda, et al.
Cancer
|
October 26, 2007
Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies
Gautam Borthakur, E Lin, Stefan Faderl, et al.
Leukemia & Lymphoma
|
October 30, 2009
p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy
Ellen J Schlette, Joan Admirand, William Wierda, et al.
Haematologica
|
January 25, 2012
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy
Naveen Pemmaraju, Hagop Kantarjian, Jianqin Shan, et al.
Blood
|
October 30, 2010
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
Elias Jabbour, Hagop Kantarjian, Susan O'Brien, et al.
Blood
|
January 10, 2015
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
Preetesh Jain, Michael Keating, William Wierda, et al.
Page
of 19